SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

Biocryst Pharmaceuticals is trending as heightened speculation around a potential buyout and unconfirmed M&A rumors drive significant after-hours volume and price volatility. Community members are actively debating the legitimacy of these reports, with long-term shareholders analyzing historical valuation metrics and potential takeover scenarios while others speculate on the motivations behind recent unusual trading patterns.

Grayscale Bitcoin Mini Trust ETF - Common units of fractional undivided beneficial interest

Grayscale Bitcoin Mini Trust ETF

The Grayscale Bitcoin Mini Trust ETF is trending as investors grapple with heightened market volatility driven by escalating geopolitical tensions and institutional debates over Bitcoin's long-term utility as a hedge. The community remains deeply divided, with bulls pointing to historical price cycles and potential regulatory breakthroughs like the Clarity Act, while bears are emphasizing downside risks linked to broader economic uncertainty and shifting institutional flow dynamics.

Bonk is a dog-themed memecoin on the Solana blockchain, launched on Christmas Day 2022 to revitalize the Solana community following the FTX collapse. Created by an anonymous team of 22 Solana developers and builders, Bonk distributed 50% of its total 100 trillion token supply via airdrop to community members including NFT collectors, developers, and artists.   The project positions itself as "the first Solana dog coin for the people, by the people," explicitly rejecting venture capital backing in favor of grassroots community ownership. What sets Bonk apart from other memecoins is its combination of fair launch mechanics, extensive ecosystem integration, and active deflationary strategy.   Built on Solana, BONK benefits from fast transaction speeds and low fees that make it practical for everyday use. Native products include LetsBonk.fun (a memecoin launchpad that briefly became Solana's market leader in 2025, surpassing Pump.fun with over 78% market share), BonkSwap (a decentralized exchange) and BonkBot (a Telegram trading bot with built-in burn mechanics).   BONK is available across 10 blockchain networks and listed on major exchanges including Binance, Coinbase, Kraken, and Robinhood. Governance is handled by BonkDAO, which holds 15% of the token supply and makes decisions through on-chain voting.   The community has organized several major burn events, most notably the December 2024 BURNmas campaign that destroyed 1.69 trillion tokens worth over $50 million. In September 2025, Nasdaq-listed Safety Shot, Inc. formed BONK Holdings LLC and acquired over 2.5% of the circulating supply (valued at $55-63 million), making BONK one of the first memecoins to attract formal corporate treasury adoption. Core contributor Nom was appointed to Safety Shot's board, and the company holds a 10% revenue share in LetsBonk.fun.  As with all memecoins, BONK is a highly speculative asset with substantial volatility. Its value is primarily driven by community sentiment, social media momentum, and meme culture rather than traditional utility.   The anonymous team, while common in the memecoin space, means investors should exercise appropriate caution. Despite these risks, Bonk has established itself as one of the most successful community-driven tokens in the Solana ecosystem, approaching 1 million unique holders and expanding from a simple memecoin into meaningful DeFi infrastructure.

BONK

BONK is trending as the community debates its long-term potential, with bullish sentiment fueled by anticipation of a massive token burn event and high holder growth, while skeptics express frustration over recent price stagnation. Investors are actively discussing the token's correlation with the broader meme coin market and monitoring the performance of the BONK ecosystem to gauge the next leg of momentum.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir Technologies is experiencing significant volatility as market participants debate the stock's valuation amid high-profile AI growth narratives and concerns regarding geopolitical contract risks. The community remains deeply polarized, with active discussions focusing on whether the company represents a high-growth essential technology play or an overvalued asset prone to broader sector pullbacks.

DoorDash, Inc. engages in the design, development, and operation of a food delivery and logistics platform. It serves consumers in the United States, Canada, and Australia. The company was founded by Andy Fang, Tony Xu, Stanley Tang, and Evan Moore on January 12, 2013 and is headquartered in San Francisco, CA.

DoorDash Inc - Ordinary Shares - Class A

DoorDash is experiencing significant market volatility as investors weigh the company's aggressive growth and AI integration against concerns over margin pressure and sector-wide regulatory headwinds. While the community remains divided over the long-term sustainability of the gig delivery model, bullish participants are closely watching volume patterns and potential support levels to determine if the stock can sustain its current valuation amid fierce competition.

Ciena Corp. is a network technology company, which engages in the provision of hardware, software, and services to network operators, as well as enabling enhanced network capacity, service delivery, and automation. It operates through the following segments: Networking Platforms, Platform Software and Services, Blue Planet Automation Software and Services, and Global Services. The Networking Platforms segment consists of converged packet optical and packet networking portfolios. The Platform Software and Services segment provides analytics, data, and planning tools to assist customers in managing its networking platforms products. The Blue Planet Automation Software and Services segment enables customers to implement large-scale software and IT-led OSS transformations by transforming legacy networks into service ready networks. The Global Services segment offers a broad suite of value-added services. The company was founded by Patrick H. Nettles and Kevin Brian Kimberlin in 1992 and is headquartered in Hanover, MD.

CIENA Corp.

Ciena Corp is drawing investor attention as it solidifies its role in the critical AI infrastructure and photonics supply chain, with the community closely tracking recent gains and the potential for the optics sector to emerge as a key market leader. Traders are actively debating whether to capitalize on this upward momentum or manage risk amid broader sector volatility and technical test points.

Coherent Corp. engages in the development, refinement, manufacturing, and marketing of engineered materials, opto-electronic components and devices, and lasers for use in the industrial, communications, electronics, and instrumentation markets. It operates through the following segments: Networking, Materials, and Lasers. The Networking segment leverages compound semiconductor technology platforms and deep knowledge of end-user applications. The Materials segment markets engineered materials and optoelectronic devices. The Lasers segment serves industrial customers in semiconductor capital equipment, display capital equipment, precision manufacturing, and aerospace and defense, as well as instrumentation customers in life sciences and scientific research. The company was founded by Carl J. Johnson in 1971 and is headquartered in Saxonburg, PA.

Coherent Corp

Coherent Corp is trending as investors aggressively position in the AI infrastructure supply chain, specifically betting on the necessity of high-speed photonics and optical interconnects. Community sentiment remains focused on the company's role as a mission-critical supplier for hyperscalers, with active discussions weighing the stock's recent price volatility against its strategic importance in overcoming bandwidth bottlenecks.

Nu Holdings Ltd. is a holding company, which engages in the provision of digital banking services. The company was founded by David Vélez Osorno, Cristina Helena Zingaretti Junqueira, and Adam Edward Wible on February 26, 2016 and is headquartered in George Town, Cayman Islands.

Nu Holdings Ltd - Ordinary Shares Class A

Nu Holdings Ltd

Nu Holdings is facing significant volatility and investor frustration as the stock struggles to sustain upward momentum, leading to heavy discussion around its repetitive price suppression and perceived institutional manipulation. While bulls remain focused on the company's long-term fintech growth, global expansion efforts, and potential U.S. banking license as core catalysts, bears and weary retail traders are voicing deep disappointment over stagnant price action and recent technical weakness.

Select Sector SPDR Trust (The) - State Street Financial Select Sector SPDR ETF

Financial Select Sector SPDR Fund

The Financial Select Sector SPDR Fund (XLF) is currently trending as investors weigh strong Q4 earnings against concerns surrounding potential credit card interest rate caps and broader systemic risks in private credit. While some market participants are rotating into financials as a defensive move, the community is actively debating whether current price action indicates a healthy sector rotation or a warning sign of an impending liquidity crunch.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class C

Alphabet is facing heightened volatility driven by the emergence of its TurboQuant memory compression technology, which is sparking market concerns over future memory chip demand, alongside ongoing regulatory antitrust scrutiny in Turkey. While investors are actively debating these headwinds, the broader community remains focused on whether these developments represent a temporary headline-driven dip or a shift in the long-term competitive landscape for AI infrastructure.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Fortress Biotech (NASDAQ:FBIO) Issues Quarterly Earnings Results, Misses Estimates By $0.32 EPS

Fortress Biotech (NASDAQ:FBIO - Get Free Report) posted its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, missing the...

Fortress Biotech (NASDAQ:FBIO) Lowered to Hold Rating by Wall Street Zen

Wall Street Zen cut shares of Fortress Biotech from a "buy" rating to a "hold" rating in a report on Saturday...

Fortress Biotech (FBIO) Projected to Post Quarterly Earnings on Monday

Fortress Biotech (NASDAQ:FBIO) will be releasing its Q4 2025 earnings before the market opens on Monday, March 30. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-3-30-fortress-biotech-inc-stock...

Fortress Biotech (NASDAQ:FBIO) Cut to "Hold" at Zacks Research

Zacks Research downgraded Fortress Biotech from a "strong-buy" rating to a "hold" rating in a research note on Monday...

Fortress Biotech (NASDAQ:FBIO) Shares Pass Above Two Hundred Day Moving Average   - What's Next?

Fortress Biotech (NASDAQ:FBIO) Share Price Crosses Above Two Hundred Day Moving Average - What's Next...

Fortress Biotech (NASDAQ:FBIO) Stock Passes Above Two Hundred Day Moving Average - Here's Why

Fortress Biotech (NASDAQ:FBIO) Stock Passes Above 200 Day Moving Average - Should You Sell...

<ul class="summary-bullets"><li>The unit is selling the voucher for $205 million, the company said.&nbsp;</li><li>20% of the proceeds from the voucher sale is owed to the Eunice Kennedy Shriver National Institute of Child Health and Human Development.&nbsp;</li><li>The voucher was issued upon approval of ZYCUBO last month for the treatment of Menkes disease, a rare genetic disorder, in pediatric patients.</li></ul>Shares of Fortress Biotech, Inc. (FBIO) rose 10% on Monday after the company announced that its majority-owned unit will sell its voucher for expedited review of a drug application by the U.S. Food and Drug Administration (FDA) for $205 million.Fortress <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2026/02/23/3242714/28889/en/UPDATE-Fortress-Biotech-s-Subsidiary-Cyprium-Therapeutics-Enters-into-Agreement-to-Sell-Rare-Pediatric-Disease-Priority-Review-Voucher-for-205-Million.html">said</a> that its unit Cyprium Therapeutics, Inc. has entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) to Sentynl Therapeutics, Inc, a U.S.-based biopharmaceutical company wholly-owned by Zydus Lifesciences Limited.Twenty percent of the proceeds from the voucher sale is owed to the Eunice Kennedy Shriver National Institute of Child Health and Human Development, the company said, while also noting that the transaction is subject to customary closing conditions.The PRV program aims to incentivize drug development for rare pediatric diseases.<h2 class="st-heading-2">Cyprium, Sentynl History</h2>Sentynl took over responsibility for the development and commercialization of the drug ZYCUBO from Cyprium in December 2023. Zycubo was approved by the FDA in January for the treatment of Menkes disease, a rare genetic disorder, in pediatric patients. The voucher was issued upon approval of ZYCUBO.Fortress said on Monday that it remains eligible to receive tiered royalties on net sales of ZYCUBO and up to $129 million in aggregate development and sales milestones from Sentynl.“With the PRV sale and three FDA approvals received in the last 15 months for Emrosi, UNLOXCYT, and ZYCUBO, in addition to the recent sale of our former subsidiary Checkpoint Therapeutics to Sun Pharma, we believe that we are well positioned to continue to execute on our portfolio,” said Fortress CEO Lindsay A. Rosenwald.<h2 class="st-heading-2">Cyprium’s Pipeline</h2>Menkes disease is a rare genetic disorder leading to impaired copper transport throughout the body. It causes low copper levels in the brain, resulting in rapid neurodegeneration, seizures, and more. Cyprium is also developing a gene therapy to deliver working copies of the copper transporter that is defective in patients with Menkes disease, and to be used in combination with ZYCUBO. The gene therapy is currently in pre-clinical development.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around FBIO shares jumped from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘high’ levels.A Stocktwits user expressed optimism for the gene therapy trial data sending the stock skyrocketing. In the short term, the user expects the company to be buoyed by royalties from its Menkes drug, and in the long term, from the gene therapy.<stembedurl>https://www.stocktwits.com/buymoremakemore/message/645614222</stembedurl><a href="https://stocktwits.com/symbol/FBIO">FBIO stock</a> has more than doubled over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/gossamer-bio-stock-plummeted-today-what-is-behind-the-crash/cZRtwTVR4ym">Gossamer Bio Stock Plummeted 82% Today — What’s Behind The Crash?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Fortress Biotech logo is displayed on the screen of a tablet.

FBIO Shares Rally After Unit Sells Priority Review Voucher For $205 Million: Retail Now Pins Hopes On Gene Therapy 

Fortress said that its majority-owned unit Cyprium Therapeutics has entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher to Sentynl Therapeutics. 

Equity

Fortress said that its majority-owned unit Cyprium Therapeutics has entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher to Sentynl Therapeutics. 


Fortress Biotech's (FBIO) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated a "buy" rating and issued a $17.00 price objective on shares of Fortress Biotech in a research report on Monday...

Fortress Biotech (NASDAQ:FBIO) Shares Cross Above 200-Day Moving Average - Here's What Happened

Fortress Biotech (NASDAQ:FBIO) Stock Price Crosses Above 200-Day Moving Average - Time to Sell...

Fortress Biotech (NASDAQ:FBIO) Shares Cross Above 200-Day Moving Average - What's Next?

Fortress Biotech (NASDAQ:FBIO) Share Price Passes Above 200-Day Moving Average - Here's Why...

Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. It operates through the Dermatology Product Sales and Pharmaceutical and Biotechnology Product Development segments. Its products include Ximino, Targadox, Exelderm, Ceracade, and Luxamend. The company was founded in 2006 and is headquartered in Bay Harbor Islands, FL.

Fortress Biotech Inc

Opendoor ($OPEN)

Strategy ($MSTR)

American Eagle ($AEO)

Ondas Inc. ($ONDS)

The stock that proved the power of the crowd. Fueled by community energy and social momentum, this winner captivated retail investors regardless of what the "experts" or traditional fundamentals had to say.

FBIO
Fortress Biotech Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest FBIO News

FBIOFortress Biotech Inc